Companies › Eccogene
2 active drug programs in 5 registered trials: 3 Phase 2, 2 Phase 1; Metabolic and endocrine, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ECC4703 Thyroid hormone receptor beta isoform (THRβ) agonist | NR1H3 | Phase 2 | Adult Obesity; Metabolic Dysfunction-associated Steatohepatitis; Non-alcoholic Fatty Liver Disease (NAFLD); Metabolic Dysfunction-Associated Steatohepatitis | Dec 2026 |
| ECC0509 Semicarbazide sensitive amine oxidase (SSAO) inhibitor | AOC3 | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07505303 | ECC4703 | Phase 2 | Adult Obesity | Metabolic and endocrine | Oct 2026 |
| NCT07726368 | ECC4703 | Phase 1 | Non-alcoholic Fatty Liver Disease (NAFLD) | Gastroenterology | Dec 2026 |
| NCT07334080 | ECC4703 | Phase 1 | Metabolic Dysfunction-Associated Steatohepatitis | Metabolic and endocrine | Apr 2027 |
| NCT07288138 | ECC4703 | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis | Metabolic and endocrine | Sep 2027 |
| NCT07288138 | ECC0509 | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis | Metabolic and endocrine | Sep 2027 |
Marea Therapeutics Rivus Pharmaceuticals Rare Thyroid Therapeutics International Eddingpharm (Zhuhai) Ribotek Biopharmaceuticals (Shandong)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.